Astellas' Isavuconazonium Should Pass Ad Comm Meeting For 2 Indications

There may be stronger antifungals on the market, but due to resistance and tolerability issues, isavuconazonium fills an unmet need and Ad Comm will recommend that it be approved. Isavuconazonium's place in therapy will be behind generics but ahead of Noxafil, which has a more limited spectrum of activity.

http://ift.tt/1BEPhQh